Calithera Biosciences (STU:2CB0) Construction In Progress : €0.00 Mil (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Construction In Progress?

Calithera Biosciences Construction In Progress Historical Data

The historical data trend for Calithera Biosciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Construction In Progress Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Calithera Biosciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Calithera Biosciences (STU:2CB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines